CNTB (Connect Biopharma) Q2 Earnings and today's 10% surge

Connect Biopharma Q2 earning were announced yesterday.

Key Numbers (Q2 ended June 30, 2026):

• License & collaboration revenue: $2.8 million (vs. $48k prior year; driven by Simcere regulatory milestone)

• Net loss: $17.3 million, or ($0.27)/share (vs. $12.9M / $0.23 prior year)

• R&D expenses: $16.3 million

• Cash, cash equivalents & short-term investments: $31.5 million (expected runway ≥1 year)

Pipeline Update:

• Completed enrollment in both Phase 2 Seabreeze STAT studies of rademikibart (for acute exacerbations in asthma and COPD)

• Topline results expected in September 2026

Summary:
Revenue beat on the Simcere milestone.

Wider loss reflects higher R&D spend tied to completing Phase 2 enrollment. Near-term catalyst is the September data readouts.